Abstracts Archive - Page 1391 of 2425 - ACR Meeting Abstracts

Abstract Number: 2782 • 2017 ACR/ARHP Annual Meeting
Patient Beliefs and Preference to Initiate a Proposed Medication in Rheumatoid Arthritis
Richard W Martin¹, Rohit Nallani², Andrew D Head¹, Aaron T Eggebeen¹, James D Birmingham¹ and Eric T Slavin¹, ¹Medicine, Rheumatology, Michigan State University, College of Human Medicine, Grand Rapids, MI, ²Michigan State University, College of Human Medicine, Grand Rapids, MI
Background/Purpose : Normative economic theory assumes that people making decisions have complete information of the options, rationally weigh the opportunity costs, expected outcomes and optimize…
Abstract Number: 2783 • 2017 ACR/ARHP Annual Meeting
Medications Associated with Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro², Frederick Wolfe² and Kaleb Michaud¹, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Osteoporotic (OP) fractures are a major cause of disability, cost, and mortality in RA. Besides increased OP fracture risk, chronic inflammation and pain predispose…
Abstract Number: 2784 • 2017 ACR/ARHP Annual Meeting
Are We over-Testing for Liver Enzyme Abnormalities in Rheumatoid Arthritis Patients Prescribed Methotrexate?
Chi Chi Lau¹, Syeda Maria Sayeed¹, Amanda Kennedy², Joan Skelly³ and Sheldon Cooper⁴, ¹Rheumatology/ Medicine, University of Vermont, Burlington, VT, ²Internal Medicine, University of Vermont, Burlington, VT, ³Biostatistics, University of Vermont, Burlington, VT, ⁴Department of Medicine/Rheumatology, University of Vermont, Burlington, VT
Background/Purpose: Methotrexate (MTX) is a first line drug for Rheumatoid Arthritis (RA) that is associated with elevated liver function tests (LFTs) in 10- 20%…
Abstract Number: 2785 • 2017 ACR/ARHP Annual Meeting
Serious Infections Associated with Tofacitinib in Rheumatoid Arthritis Patients Previously Treated with Methotrexate
Marina Amaral de Avila Machado¹, Cristiano S. Moura², Steve Ferreira Guerra¹, Jeffrey R. Curtis³, Michal Abrahamowicz⁴, Hassan Behlouli¹ and Sasha Bernatsky⁵, ¹Department of Medicine, McGill University Health Centre, Montreal, QC, Canada, ²1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, McGill University Health Centre, Montreak, QC, Canada, ⁵Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Little is known about the real-world safety of tofacitinib, an oral Janus kinase inhibitor. We compared serious infections associated with tofacitinib, disease-modifying antirheumatic drugs…
Abstract Number: 2786 • 2017 ACR/ARHP Annual Meeting
Timing of Abatacept Infusions before Elective Arthroplasty and the Risk of Post-Operative Infection
Michael D. George¹, Joshua Baker², Kevin Winthrop³, E Alemao⁴, Lang Chen⁵, SE Connolly⁴, TA Simon⁴, Qufei Wu⁶, Fenglong Xie⁷, Shuo Yang⁷ and Jeffrey R. Curtis⁸, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Oregon Health Sciences University, Portland, OR, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Current guidelines recommend holding biologic DMARDs before major surgery, despite limited data. Few studies have examined perioperative timing of individual biologic therapies. This study…
Abstract Number: 2787 • 2017 ACR/ARHP Annual Meeting
Tuberculosis, Potential Opportunistic Infections, and Other Infections of Interest in Patients with Moderate to Severe Rheumatoid Arthritis in the Baricitinib Program
Kevin Winthrop¹, Stephen Lindsey², Masayoshi Harigai³, John D. Bradley⁴, Lei Chen⁴, David L. Hyslop⁴, Maher Issa⁴, Atsushi Nishikawa⁵, Sarah Witt⁴, Christina L. Dickson⁴ and Maxime Dougados⁶, ¹Oregon Health & Science University, Portland, OR, ²Ochsner Health Center, Baton Rouge, LA, ³Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Lilly Japan K.K., Kobe, Japan, ⁶Rene Descartes University, Cochin Hospital, Paris, France
Background/Purpose: Baricitinib (bari) is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor approved in the EU for the treatment (trt) of moderately to…
Abstract Number: 2788 • 2017 ACR/ARHP Annual Meeting
The Risk of Major Toxicity with Aspirin for Primary Cardiovascular Prevention in Rheumatoid Arthritis Patients Using Nsaids: A Secondary Cohort Analysis of a Randomized Controlled Clinical Trial
Daniel H. Solomon¹, Peter Libby², Qiuquing Wang³, Katherine E Wolski⁴, Lisa M Wisniewski⁴, Neville Yeomans⁵, Michael Lincoff⁶, Steven E Nissen⁷ and M. Elaine Husni⁸, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Cardiology, Brigham and Women's Hospital, Boston, MA, ³Cleveland Clinic, Cleveland, OH, ⁴Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ⁵Western Sydney Medical School, Sydney, Australia, ⁶Cardiology, Cleveland Clinic Foundation, Cleveland, OH, ⁷Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: There are relatively clear guidelines for the use of low dose aspirin in the general population for primary cardiovascular (CV) prevention, but the risk-benefit…
Abstract Number: 2789 • 2017 ACR/ARHP Annual Meeting
Deficiency of the Novel Rheumatoid Arthritis (RA) Risk Gene, LBH, Induces Replication Stress in RA Fibroblast-like Synoviocytes (FLS) and Exacerbates Arthritis Severity
Shinji Matsuda¹, Deepa Hammaker², Katheryn Topolewski³, Karoline Briegel⁴, Steven Dowdy⁵, David L. Boyle⁶, Wei Wang⁷ and Gary S. Firestein⁸, ¹Medicine, UC San Diego, La Jolla, CA, ²Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ³UC San Diego, La Jolla, CA, ⁴University of Miami, Miami, FL, ⁵UC San Diego School of Medicine, La Jolla, CA, ⁶University of California San Diego, La Jolla, CA, ⁷Chemistry and Biochemistry, UC San Diego, La Jolla, CA, ⁸Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: LBH (Limb-bud and heart development) was recently identified as an RA risk gene that has abnormally methylated loci and a functional enhancer SNP in…
Abstract Number: 2790 • 2017 ACR/ARHP Annual Meeting
Regulation of ASK1 Expression and Its Role in Rheumatoid Arthritis (RA)
Gyrid Nygaard¹, Deepa Hammaker², David L. Boyle³, Li Li⁴, Julie Di Paolo⁵ and Gary S. Firestein⁶, ¹Medicine, UC San Diego, La Jolla, CA, ²Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ³University of California San Diego, La Jolla, CA, ⁴Gilead Sciences, South San Francisco, CA, ⁵Immunology and Inflammation Biology, Gilead Sciences, Foster City, CA, ⁶Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) reside in the synovial intimal lining. They display a unique aggressive phenotype, invading the articular cartilage and promoting…
Abstract Number: 2791 • 2017 ACR/ARHP Annual Meeting
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Marginal Jawbone Loss Predates the Onset of Rheumatoid Arthritis
Elin Kindstedt¹, Linda Johansson², Py Palmqvist³, Cecilia Koskinen Holm¹, Heidi Kokkonen⁴, Ingegerd Johansson³, Pernilla Lundberg³ and Solbritt Rantapaa-Dahlqvist⁵, ¹1Department of Odontology/Molecular Periodontology, Umeå University, Umeå, Sweden, ²Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Department of Odontology/Molecular Periodontology, Umeå University, Umeå, Sweden, ⁴Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ⁵Dept of Public Health and Clinical Medicine/Rheumatology, Umeå University, Sweden, Umeå, Sweden
Background/Purpose: Previous studies have shown a higher incidence of alveolar bone loss in patients with rheumatoid arthritis (RA) and that patients with periodontitis are at…
Abstract Number: 2792 • 2017 ACR/ARHP Annual Meeting
Th22 Cells Are a Potent Inducer of Osteoclastogenesis in Rheumatoid Arthritis
Yusuke Miyazaki¹, Shingo Nakayamada², Satoshi Kubo¹, Kazuhisa Nakano², Kei Sakata³, Shigeru Iwata⁴, Ippei Miyagawa⁵ and Yoshiya Tanaka⁶, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyshu, Japan, ⁴First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: CD4+ T cells can differentiate into functionally distinct subsets and play a pivotal role in rheumatoid arthritis (RA). Th22 cells have been identified as…
Abstract Number: 2793 • 2017 ACR/ARHP Annual Meeting
Joint Location-Specific JAK-STAT Signaling in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS)
Deepa Hammaker¹, Gyrid Nygaard¹, David L. Boyle², Rizi Ai³, Wei Wang⁴ and Gary S. Firestein⁵, ¹Medicine, UC San Diego, La Jolla, CA, ²University of California San Diego, La Jolla, CA, ³UC San Diego, La Jolla, CA, ⁴Chemistry and Biochemistry, UC San Diego, La Jolla, CA, ⁵Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: Aberrant epigenetic marks in RA FLS contribute to disease pathogenesis and aggressive FLS behavior. Computational data also suggest that RA FLS isolated from different…
Abstract Number: 2794 • 2017 ACR/ARHP Annual Meeting
Apolipoprotein B Binds to Enolase-1 and Aggravates Inflammation in Rheumatoid Arthritis
Joo Youn Lee¹, Min Jueng Kang¹, Ji Yong Choi², Ji Soo Park³, Jin Kyun Park^1,2, Eun Young Lee⁴, Eun Bong Lee⁵, Thomas Pap⁶, Eugene Yi¹ and Yeong Wook Song^1,2, ¹Department of Molecular medicine and biopharmaceutical science, Seoul National University, seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, Korea, Republic of (South), ³Department of Molecular medicine and biopharmaceutical science, Seoul National University, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, seoul, Korea, Republic of (South), ⁶Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by synovial inflammation and joint destruction. Monocytes and synovial macrophages are key players in…
Abstract Number: 2795 • 2017 ACR/ARHP Annual Meeting
Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re‑Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: Safety and Immunogenicity Results from a Multicenter, Randomized, Double-Blind Study
Hans-Peter Tony¹, Hendrik Schulze-Koops², Klaus Krüger³, Stanley B Cohen⁴, Alan J. Kivitz⁵, Slawomir Jeka⁶, Edit Vereckei⁷, Liyi Cen⁸ and Dmitrij Kollins⁸, ¹Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ³Praxiszentrum St. Bonifatius München, München, Germany, ⁴Metroplex Clinical Research Centre, Dallas, TX, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶2nd University Hospital, CM UMK, Department of Rheumatology and Connective Tissue Diseases,, Bydgoszcz, Poland, ⁷National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁸Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany
Background/Purpose: GP2013, is a biosimilar to European Union (EU) approved reference rituximab (RTX), developed in a stepwise approach that adheres to stringent biosimilar development guidelines.…
Abstract Number: 2796 • 2017 ACR/ARHP Annual Meeting
A Randomized, Double Blind Trial over 52 Weeks to Demonstrate Bioequivalence of GP2013 and Reference Rituximab in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Stanley B Cohen², Morton Scheinberg³, Tamas Shisha⁴, Dmitrij Kollins⁴, Peijuan Zhu⁵, Liyi Cen⁴, Alan J. Kivitz⁶, Andra Rodica Balanescu⁷, Juan J. Gomez-Reino⁸ and Hans-Peter Tony⁹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Metroplex Clinical Research Centre, Dallas, TX, ³Rheumatology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, ⁴Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany, ⁵Clinical Pharmacology, Sandoz, a Novartis Division, NJ, NJ, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Research Center of Rheumatic Diseases, “Sf. Maria” Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, ⁸BIOBADASER, Santiago, Spain, Santiago de Compostela, Spain, ⁹Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Rituximab (RTX) is a mAB indicated for the treatment of RA in patients with inadequate response to anti-TNF therapy. The current study compares the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].